抗癌汤联合化疗对中晚期口腔癌术后患者免疫功能及预后的影响

Effect of anti-cancer soup combined with chemotherapy on the immune function and prognosis of patients with advanced oral cavity carcinomas after surgery

目的探讨中药抗癌汤联合化疗对中晚期口腔癌术后患者免疫功能及预后的影响。方法选取60例中晚期口腔癌术后患者作为研究对象,按照随机数字表法将患者随机分为对照组和观察组,每组30例。对照组患者接受常规化疗方案进行治疗,观察组患者在常规化疗方案的基础上联合中药抗癌汤进行治疗。两组患者均连续治疗8周,并对患者进行为期2年的随访。比较两组患者的临床疗效,检测两组患者血清中肿瘤标志物的水平和T淋巴细胞亚群比例,比较两组患者随访期间的无进展生存情况。结果治疗后,观察组患者的总有效率(RR)为80.0%,高于对照组患者的53.3%(P﹤0.05)。随访期间,对照组中发生PD患者8例,观察组中发生PD患者2例;观察组患者的无进展生存率高于对照组患者,差异有统计学意义(P﹤0.05)。治疗前,两组患者的T淋巴细胞亚群比例比较,差异均无统计学意义(P﹥0.05)。治疗后,对照组患者的CD4^+细胞比例、CD4^+/CD8^+均低于本组治疗前,CD8^+细胞比例高于本组治疗前,差异均有统计学意义(P﹤0.05);但治疗前后的CD56^+细胞比例比较,差异无统计学意义(P﹥0.05)。治疗后,观察组患者的CD4^+细胞比例、CD4^+/CD8^+均高于对照组患者,CD8^+细胞比例低于对照组患者,差异均有统计学意义(P﹤0.05);但治疗后两组患者的CD56^+细胞比例比较,差异无统计学意义(P﹥0.05)。结论抗癌汤联合化疗可以有效改善中晚期口腔癌术后患者的免疫功能,提高临床疗效,同时可提高中晚期口腔癌患者的无进展生存率。

Objective To investigate the effect of anti-cancer soup combined with chemotherapy on the immune function and prognosis of patients with advanced oral cavity carcinomas after surgery. Method 60 cases with advanced oral cavity carcinomas after surgical treatment were enrolled in the study and were divided as control group or study group according to a random number table, with 30 cases in each. The patients in control group were given conventional chemotherapy, while those in study group were administered with compound traditional Chinese medicine anti-cancer soup and conventional chemotherapy at the same time, the two groups were treated for 8 consecutive weeks and followed up for 2 years. The clinical efficacy of the two groups were compared, the tumor marker level and proportion of T lymphocyte subsets were detected and compared, and the progression-free survival （PFS） of these patients during follow- up period were compared. Result After treatment, the overall response rate （RR） in study group reached 80.0%, which was higher than that of 53.3% in control group （P〈0.05）, during follow-up, there were 8 cases of progressive disease （PD） in control group, and 2 cases in study group; the PFS rate of study group was higher than that of control group, and the difference had statistical significance （P〈0.05）. Before treatment, the proportion of T lymphocyte subsets in the two groups was similar （P〉0.05）. After treatment, the proportion of CD4＋ cells, CD4＋ CD8＋ ratio in control group decreased （P〈0.05）, while the proportion of CD8＋ cells increased （P〈0.05）, though no statistically significant difference was observed for the proportion of CD56＋ cells before and after treatment （P〉0.05）. After treatment, the proportion of CD4- cells and CD4-/CD8＋ ratio in study group were higher than those in control group, but the proportion of CD8＋ was lower in study group compared with control group, showing statistically significant difference （P〈0.05）; though the proportion of CD56＋ cells in both groups after treatment was comparable, with no statistical significance observed （P〉0.05）. Conclusion Anti-cancer soup combined with chemotherapy can effectively improve the immune function of patients with advanced oral cavity carcinomas after surgery, enhancing the clinical efficacy, and may increase the survival rate of patients at the same time.